ZoBio and Actelion partnered to discover conformationally selective fragment ligands using ZoBio's Target Immobilized NMR Screening technology against an undisclosed oncology target from Actelion

ZoBio B.V.

the Netherlands / Tools, Services, and Manufacturing

Other

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Actelion Ltd.

Switzerland / Mid-Cap Biopharma ($1-$50 billion)

$9,605.1m on 11/01/2013 [market cap]

Other

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced